Breaking News

CPHI NA Panel Discussion Looks at Supply Chain Risk & Resilience Issues for U.S. CDMOs

Bikash Chatterjee of Pharmatech Associates says drug sponsors need to focus on mitigating risk and building resiliency when using smaller or mid-sized CDMOs.

Bikash Chatterjee, CEO of Pharmatech Associates, a USP company, says that CDMO supply chains are potentially the biggest single risk to product resilience, yet remain an area often overlooked by drug sponsors in partnering criteria. Chatterjee made his comments ahead of a CPHI North America panel discussion, Redesigning the Supply Chain – The Road to Increased Resilience. According to Chatterjee, with many of the largest CDMOs now running at capacity, drug sponsors will need to focus on mi...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters